101 related articles for article (PubMed ID: 25669655)
1. Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis.
Abdul Razzak R; Florence GJ; Gunn-Moore FJ
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242683
[TBL] [Abstract][Full Text] [Related]
2. Metabolite transport across central nervous system barriers.
Carstens G; Verbeek MM; Rohlwink UK; Figaji AA; Te Brake L; van Laarhoven A
J Cereb Blood Flow Metab; 2024 Jul; 44(7):1063-1077. PubMed ID: 38546534
[TBL] [Abstract][Full Text] [Related]
3. How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Le J; Talele S; Sarkaria JN; Elmquist WF
Pharm Res; 2023 Nov; 40(11):2731-2746. PubMed ID: 37589827
[TBL] [Abstract][Full Text] [Related]
4. AAV9: a potential blood-brain barrier buster.
Manfredsson FP; Rising AC; Mandel RJ
Mol Ther; 2009 Mar; 17(3):403-5. PubMed ID: 19247366
[No Abstract] [Full Text] [Related]
5. Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2- Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration.
Liu H; Yu N; Lu S; Ito S; Zhang X; Prasad B; He E; Lu X; Li Y; Wang F; Xu H; An G; Unadkat JD; Kusuhara H; Sugiyama Y; Sahi J
Drug Metab Dispos; 2015 Jul; 43(7):1008-18. PubMed ID: 25908246
[TBL] [Abstract][Full Text] [Related]
6. Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.
de Lange EC; Hammarlund-Udenaes M
Clin Pharmacol Ther; 2015 Apr; 97(4):380-94. PubMed ID: 25670219
[TBL] [Abstract][Full Text] [Related]
7. Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation.
Anoshchenko O; Storelli F; Unadkat JD
Drug Metab Dispos; 2021 Oct; 49(10):919-928. PubMed ID: 34426410
[TBL] [Abstract][Full Text] [Related]
8. An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.
Gong Y; Zhi K; Nagesh PKB; Sinha N; Chowdhury P; Chen H; Gorantla S; Yallapu MM; Kumar S
Viruses; 2020 May; 12(5):. PubMed ID: 32443728
[TBL] [Abstract][Full Text] [Related]
9. Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier.
Erdő F; Krajcsi P
Front Aging Neurosci; 2019; 11():196. PubMed ID: 31417399
[TBL] [Abstract][Full Text] [Related]
10. Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism.
Ladumor MK; Bhatt DK; Gaedigk A; Sharma S; Thakur A; Pearce RE; Leeder JS; Bolger MB; Singh S; Prasad B
Drug Metab Dispos; 2019 Aug; 47(8):818-831. PubMed ID: 31101678
[TBL] [Abstract][Full Text] [Related]
11. An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.
Han LW; Gao C; Mao Q
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):817-829. PubMed ID: 30010462
[TBL] [Abstract][Full Text] [Related]
12. Database of Optimized Proteomic Quantitative Methods for Human Drug Disposition-Related Proteins for Applications in Physiologically Based Pharmacokinetic Modeling.
Vrana M; Whittington D; Nautiyal V; Prasad B
CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):267-276. PubMed ID: 28074615
[TBL] [Abstract][Full Text] [Related]
13. Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier.
Bauer M; Römermann K; Karch R; Wulkersdorfer B; Stanek J; Philippe C; Maier-Salamon A; Haslacher H; Jungbauer C; Wadsak W; Jäger W; Löscher W; Hacker M; Zeitlinger M; Langer O
Clin Pharmacol Ther; 2016 Aug; 100(2):131-41. PubMed ID: 26940368
[TBL] [Abstract][Full Text] [Related]
14. The concept of fraction of drug transported (ft ) with special emphasis on BBB efflux of CNS and antiretroviral drugs.
Prasad B; Unadkat JD
Clin Pharmacol Ther; 2015 Apr; 97(4):320-3. PubMed ID: 25669655
[TBL] [Abstract][Full Text] [Related]
15. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.
Kalvass JC; Polli JW; Bourdet DL; Feng B; Huang SM; Liu X; Smith QR; Zhang LK; Zamek-Gliszczynski MJ;
Clin Pharmacol Ther; 2013 Jul; 94(1):80-94. PubMed ID: 23588303
[TBL] [Abstract][Full Text] [Related]
16. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
Reichel A
Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
[TBL] [Abstract][Full Text] [Related]
17. Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes.
Shawahna R; Decleves X; Scherrmann JM
Curr Drug Metab; 2013 Jan; 14(1):120-36. PubMed ID: 23215812
[TBL] [Abstract][Full Text] [Related]
18. Blood-brain barrier: an impediment to neuropharmaceuticals.
Henderson JT; Piquette-Miller M
Clin Pharmacol Ther; 2015 Apr; 97(4):308-13. PubMed ID: 25670372
[TBL] [Abstract][Full Text] [Related]
19. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
Sanchez-Covarrubias L; Slosky LM; Thompson BJ; Davis TP; Ronaldson PT
Curr Pharm Des; 2014; 20(10):1422-49. PubMed ID: 23789948
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
